Themes · Biotech_therapeutics

Narrative basket·№8 of the day·As of 2026-08-24

Human Therapeutics/ №8

Broad reference cohort for primary human-therapeutics companies.

As of 2026-08-24, Human Therapeutics ranks №8 among themes for that session with a composite score of 53/100 and median member RS of 72.

Composite: 53_/100
Median RS: 72
Breadth > 50dma: 59%
% at Highs: 17%
Accumulation: 27%
$-Vol Δ: -18%

Score history · last 60 sessionsLast 53·Range 37–72

Members_{71 tickers}

Ticker / whyRSTrendHighAccum$Vol

ERASErasca is a precision-oncology therapeutics company; the naporafenib SEACRAFT-2 study remains active, not recruiting, and Phase 3.

RS 99

-30%$39.5M$56.1M

MRNAModerna develops mRNA medicines and markets approved vaccines while maintaining a broad clinical pipeline.

RS 99

50D

+34%$4.4B$3.3B

ORKAOruka develops antibodies for inflammatory skin disease; ORKA-001 is recruiting in the Phase 2 EVERLAST-B study.

RS 99

50D

+24%$101.6M$82.1M

RVMDRevolution Medicines develops RAS-targeted cancer medicines and is advancing daraxonrasib in Phase 3 studies.

RS 98

50D

0%$338.1M$339.1M

IOVAIovance develops cell therapies and markets AMTAGVI.

RS 98

50D

ACCUM

-4%$126.8M$131.8M

PRAXPraxis develops precision neuroscience medicines and reports late-stage studies including Phase 3 development.

RS 98

50D

ACCUM

-38%$97.5M$157.5M

REPLReplimune develops oncolytic immunotherapies and reports ongoing registrational and Phase 2-or-later RP1 programs.

RS 98

50D

-66%$30.6M$88.7M

CRNXCrinetics is a therapeutics company with late-stage endocrine programs, including Phase 3 development.

RS 97

50D

HIGH

-66%$77.0M$224.0M

CORTCorcept develops cortisol-modulating medicines and markets KORLYM while advancing additional late-stage programs.

RS 97

50D

HIGH

-3%$124.8M$129.1M

QUREuniQure develops gene therapies for severe diseases and has late-stage Huntington's disease development.

RS 97

50D

ACCUM

-27%$43.7M$60.2M

TVTXTravere is a rare-disease therapeutics company that markets FILSPARI.

RS 97

50D

HIGH

-36%$67.5M$105.1M

CMPSCOMPASS is developing COMP360 psilocybin treatment for treatment-resistant depression in an active Phase 3 program.

RS 97

50D

+9%$39.4M$36.0M

ARWRArrowhead is an RNA-therapeutics company with Phase 3 programs.

RS 97

50D

-16%$95.8M$113.9M

URGNUroGen develops and commercializes uro-oncology medicines and reports marketed product revenue.

RS 96

50D

-16%$39.2M$46.4M

LQDALiquidia develops therapies for pulmonary hypertension and has a commercial therapeutics operation alongside late-stage YUTREPIA development.

RS 95

-30%$90.7M$130.1M

KYMRKymera develops targeted protein-degradation medicines; KT-621 is recruiting in a Phase 2b asthma study.

RS 95

50D

ACCUM

-25%$56.5M$75.0M

TGTXTG Therapeutics develops and commercializes BRIUMVI for relapsing multiple sclerosis.

RS 93

50D

+30%$159.4M$122.6M

ALKSAlkermes primarily develops and commercializes neuroscience medicines and has marketed products.

RS 89

-22%$63.4M$81.3M

KRYSKrystal develops genetic medicines and commercializes VYJUVEK for dystrophic epidermolysis bullosa.

RS 89

-25%$80.9M$108.2M

DNLIDenali is a neurodegenerative-disease therapeutics company with active Phase 2 programs, including partnered programs it owns economically.

RS 84

-4%$32.0M$33.2M

ZYMEZymeworks is an antibody-therapeutics company with a commercialized partnered medicine and active Phase 3 development.

RS 83

50D

HIGH

ACCUM

+85%$23.7M$12.8M

XENEXenon is a neuroscience therapeutics company with active Phase 3 azetukalner development.

RS 83

-6%$38.1M$40.7M

INCYIncyte discovers, develops, and commercializes human medicines and reports marketed hematology/oncology and dermatology products.

RS 82

50D

HIGH

-56%$102.3M$232.8M

AMGNAmgen's primary business is discovering, developing, manufacturing, and commercializing human therapeutics across oncology, inflammation, and other diseases.

RS 81

50D

HIGH

ACCUM

-3%$1.1B$1.1B

AZNAstraZeneca's primary business is human prescription medicines and it reports a large marketed portfolio.

RS 81

-35%$463.5M$717.8M

ACADACADIA is a human-neuroscience biopharmaceutical company that markets NUPLAZID and DAYBUE.

RS 80

50D

HIGH

ACCUM

-13%$44.2M$51.0M

LLYEli Lilly's primary business is human medicines and it markets a broad portfolio.

RS 79

50D

-39%$2.1B$3.4B

BHVNBiohaven is a clinical-stage human therapeutics company with multiple Phase 2-or-later neuroscience/immunology programs.

RS 79

-32%$18.5M$27.2M

ARGXargenx develops and commercializes antibody medicines, led by the marketed VYVGART franchise.

RS 78

50D

ACCUM

+14%$322.0M$283.4M

CYTKCytokinetics is a muscle-biology therapeutics company with late-stage/approved-product exposure that clears the threshold.

RS 77

-37%$93.5M$148.7M

VRTXVertex develops and commercializes medicines for cystic fibrosis, sickle cell disease, pain, and other serious diseases.

RS 77

50D

HIGH

ACCUM

-38%$420.3M$678.4M

BIIBBiogen develops and markets human neurological medicines across multiple disease areas.

RS 75

50D

HIGH

-30%$141.7M$201.2M

BMYBristol Myers Squibb's primary business is human biopharmaceuticals and it markets a broad portfolio.

RS 75

50D

HIGH

ACCUM

-43%$458.3M$806.0M

REGNRegeneron discovers, develops, manufactures, and commercializes human medicines across eye disease, immunology, oncology, and other areas.

RS 75

50D

HIGH

ACCUM

-12%$556.7M$630.6M

EXELExelixis develops and commercializes oncology medicines, led by the marketed CABOMETYX franchise.

RS 73

50D

ACCUM

-11%$132.2M$148.1M

BEAMBeam is a genetic-medicines company; BEAM-302 is recruiting in a Phase 1/2 protocol with an explicit Phase 2 dose-expansion component.

RS 72

-24%$35.3M$46.6M

ZLABZai Lab develops and commercializes human medicines and reports multiple marketed products.

RS 71

50D

0%$29.5M$29.4M

GMABGenmab's primary business is antibody therapeutics and its marketed/partnered commercial products satisfy the rule.

RS 70

50D

ACCUM

+24%$107.2M$86.8M

ABBVAbbVie's primary business is human biopharmaceuticals and it markets a broad portfolio; it meets the written rule but is absent from the 37-name roster.

RS 70

50D

HIGH

-25%$1.0B$1.4B

RYTMRhythm develops and commercializes medicines for rare neuroendocrine diseases and markets IMCIVREE.

RS 66

50D

ACCUM

-44%$44.6M$79.6M

BMRNBioMarin develops and commercializes medicines for rare genetic diseases and reports a multi-product commercial portfolio.

RS 64

50D

-2%$147.3M$150.4M

ARQTArcutis is a medical-dermatology therapeutics company that markets ZORYVE.

RS 63

-39%$28.0M$46.0M

IMCRImmunocore develops T-cell receptor therapeutics and markets KIMMTRAK.

RS 62

50D

-7%$13.6M$14.6M

NTLAIntellia develops in-vivo and ex-vivo CRISPR medicines and has late-stage hereditary-angioedema development.

RS 62

-5%$39.1M$41.3M

TAKTakeda's primary business is human pharmaceuticals and it markets a broad portfolio.

RS 62

50D

ACCUM

-35%$40.7M$62.5M

MIRMMirum develops rare-disease therapeutics and markets LIVMARLI and CHOLBAM.

RS 60

-51%$35.6M$72.7M

TARSTarsus is an eye-care therapeutics company that markets XDEMVY.

RS 59

50D

-37%$30.1M$47.9M

UTHRUnited Therapeutics develops and commercializes therapies for pulmonary hypertension and other serious diseases.

RS 59

-41%$166.1M$279.9M

ASNDAscendis is a human therapeutics company with marketed endocrine rare-disease medicines.

RS 59

-39%$83.1M$136.3M

GILDGilead develops and commercializes human medicines in virology, oncology, and inflammation.

RS 58

50D

-1%$907.3M$912.7M

CRSPCRISPR Therapeutics develops gene-edited medicines and co-commercializes the approved therapy CASGEVY with Vertex.

RS 57

50D

ACCUM

-24%$63.9M$83.9M

NVSNovartis is a focused human innovative-medicines company with a broad marketed portfolio.

RS 56

50D

-47%$126.6M$240.0M

PTCTPTC develops rare-disease therapeutics and reports commercial products plus late-stage programs.

RS 55

-28%$63.8M$88.6M

PFEPfizer's primary business is human biopharmaceuticals and it markets a broad portfolio.

RS 53

50D

ACCUM

-38%$666.3M$1.1B

NBIXNeurocrine develops and commercializes neuroscience medicines, led by INGREZZA and other approved products.

RS 53

-23%$184.9M$239.5M

SNDXSyndax is an oncology therapeutics company that commercializes REVUFORJ.

RS 51

+3%$28.3M$27.3M

VKTXViking develops metabolic and endocrine therapies and is advancing VK2735 in late-stage obesity studies.

RS 51

-9%$58.1M$64.0M

MDGLMadrigal is a human therapeutics company that markets REZDIFFRA.

RS 51

-63%$74.5M$200.3M

GSKGSK's primary business is human medicines and vaccines and it markets a broad portfolio.

RS 50

-27%$149.4M$204.9M

SRPTSarepta develops genetic medicines for rare diseases and reports marketed Duchenne muscular dystrophy therapies.

RS 47

50D

-51%$25.0M$50.9M

NVONovo Nordisk's primary business is human therapeutics and it markets diabetes, obesity, and rare-disease medicines.

RS 44

ACCUM

-31%$453.9M$662.1M

RAREUltragenyx develops and commercializes medicines for rare and ultra-rare genetic diseases.

RS 42

-29%$39.5M$55.8M

SNYSanofi's primary business is human medicines and vaccines and it markets a broad portfolio.

RS 37

50D

-43%$78.6M$138.3M

INSMInsmed is a biopharmaceutical company focused on serious and rare diseases and markets ARIKAYCE while advancing late-stage programs.

RS 32

50D

-55%$166.3M$366.4M

IONSIonis develops RNA-targeted medicines and commercializes owned medicines while earning revenue from partnered products.

RS 32

-1%$136.9M$138.1M

RXRXRecursion is a clinical-stage human therapeutics company despite its technology platform framing and reports active Phase 2 programs.

RS 31

-6%$49.1M$52.4M

ADMAADMA develops, manufactures, and markets plasma-derived immune-globulin therapeutics including BIVIGAM, ASCENIV, and Nabi-HB.

RS 21

50D

-17%$18.7M$22.5M

LEGNLegend Biotech develops cell therapies and has commercial exposure to CARVYKTI.

RS 18

-32%$40.4M$59.8M

ALNYAlnylam develops and commercializes RNA-interference medicines and reports a multi-product marketed portfolio.

RS 12

ACCUM

-6%$504.4M$536.1M

CAPRCapricor is a human cell-therapy developer with an active Phase 3 Duchenne muscular dystrophy program.

RS 10

+79%$136.5M$76.2M

ADCTADC Therapeutics is a human oncology therapeutics company that markets ZYNLONTA.

RS 4

-56%$618K$1.4M

Loading…

Members71 tickers

Members71 tickers

Members_{71 tickers}

Members_{71 tickers}